Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where E. C. M. van Gorp is active.

Publication


Featured researches published by E. C. M. van Gorp.


Journal of Infection | 2010

The diagnostic role of Procalcitonin and other biomarkers in discriminating infectious from non-infectious fever

M. Limper; M.D. de Kruif; Ashley J. Duits; D.P.M. Brandjes; E. C. M. van Gorp

Fever is not only observed in the course of a bacterial or viral infection, but can be a symptom of, for instance, auto-immune, malignant or thromboembolic disease. Determining the etiology of fever in a fast and reliable way is of pivotal importance, as different causes of fever may ask for different therapies. Neither clinical signs and symptoms, nor traditional biomarkers, such as CRP, leukocytes and ESR have sufficient sensitivity and specificity to guide treatment decisions. In this review we focus on the value of traditional and newer biomarkers in non-infectious febrile diseases. Procalcitonin (PCT) seems to be the most helpful laboratory marker for the differentiation of causes of fever, particularly in autoimmune, autoinflammatory and malignant diseases.


The Journal of Infectious Diseases | 1999

Review: Infectious Diseases and Coagulation Disorders

E. C. M. van Gorp; C. Suharti; H. ten Cate; W.M.V. Dolmans; J.W.M. van der Meer; J. W. Ten Cate; D. P. M. Brandjes

Infection, both bacterial and nonbacterial, may be associated with coagulation disorders, resulting in disseminated intravascular coagulation and multiorgan failure. In the last few decades a series of in vivo and in vitro studies has provided more insight into the pathogenetic mechanisms and the role of cytokines in these processes. Because of the growing interest in this field, the complexity of the subject, and the fact that many physicians must deal with a variety of infections, current data are reviewed on the association between infectious diseases and the coagulation system. Novel therapeutic intervention strategies that will probably become available in the near future are mentioned, along with those of special interest for infectious disorders for which only supportive care can be given.


European Journal of Clinical Microbiology & Infectious Diseases | 2004

Dengue: an arthropod-borne disease of global importance.

A. T. A. Mairuhu; Jiri F. P. Wagenaar; D. P. M. Brandjes; E. C. M. van Gorp

Dengue viruses cause a variable spectrum of disease that ranges from an undifferentiated fever to dengue fever to the potentially fatal dengue shock syndrome. Due to the increased incidence and geographical distribution of dengue in the last 50 years, dengue is becoming increasingly recognised as one of the world’s major infectious diseases. This article will review clinical and diagnostic aspects of dengue virus infections. It also presents our current knowledge of the pathophysiology of severe dengue and addresses the importance of dengue virus infections in those travelling to parts of the world where dengue is endemic.


Tropical Medicine & International Health | 2006

What role do coagulation disorders play in the pathogenesis of leptospirosis

Jiri F. P. Wagenaar; Marga G. A. Goris; M. S. Sakundarno; Muhammad Hussein Gasem; A. T. A. Mairuhu; M.D. De Kruif; H. ten Cate; Rudy A. Hartskeerl; D. P. M. Brandjes; E. C. M. van Gorp

Leptospirosis is a zoonosis of worldwide distribution, spread by the urine of infected animals. It is a major public health problem, especially in developing countries, where circumstances for transmission are most favourable. The clinical picture varies from mild disease to a severe illness with haemostatic derangements and multiorgan failure eventually leading to death. Although the haemorrhagic complications of severe disease are serious, the pathophysiology is scarcely elucidated. The complex mechanisms involved in inflammation‐induced coagulation activation are extensively studied in various infectious diseases, i.e. Gram‐negative sepsis. Tissue factor‐mediated coagulation activation, impairment of anticoagulant and fibrinolytic pathways in close concert with the cytokine network are thought to be important. But for human leptospirosis, data are limited. Because of the growing interest in this field, the impact of leptospirosis, and the availability of new therapeutic strategies, we reviewed the evidence regarding the role of coagulation in leptospirosis and provide suggestions for future research.


Thrombosis and Haemostasis | 2010

The effect of initiating combined antiretroviral therapy on endothelial cell activation and coagulation markers in South African HIV-infected individuals.

E. Jong; Susan Louw; E. C. M. van Gorp; J. C. M. Meijers; H. ten Cate; Barry F. Jacobson

An increased incidence of venous thromboembolism (VTE) is observed in human immunodeficiency virus (HIV)-infected patients. Only a limited number of studies described the effect of combined antiretroviral therapy (cART) on coagulation markers. In a prospective cohort study in cART-naive South African HIV-infected individuals the effect of initiating cART on markers of endothelial cell activation, coagulation and natural anticoagulation was studied. These markers were compared to the reference ranges for an HIV-uninfected control population recruited from hospital staff. A venous ultrasound of both legs was performed to detect asymptomatic deep venous thrombosis (DVT). A total number of 123 HIV-infected participants were included. The patients were predominantly black and severely immuno-compromised. The CD4 cell count increased and the HIV viral load decreased significantly after the initiation of cART (p<0.001). The median follow-up period was 7.2 (± 1.6) months. Laboratory testing before and after initiation of cART was completed by 86 patients. Before initiating cART significantly elevated von Willebrand factor and D-dimer levels, increased activated protein C sensitivity ratio (APCsr) and decreased total and free protein S and protein C levels were observed compared to HIV-negative controls. At follow-up all markers, except APCsr, improved towards the normal range for controls without showing complete normalisation. In a subgroup of 57 patients no asymptomatic DVT was found. Compared to the controls, abnormal levels of coagulation markers were observed in HIV-infected individuals before and after the initiation of cART. Most markers improved after starting cART, but remained significantly different from the controls, indicating a persistent disturbed haemostatic balance.


Tropical Medicine & International Health | 2010

Coagulation disorders in patients with severe leptospirosis are associated with severe bleeding and mortality

Jiri F. P. Wagenaar; Marga G. A. Goris; D. L. Partiningrum; Bambang Isbandrio; Rudy A. Hartskeerl; D. P. M. Brandjes; Joost C. M. Meijers; Muhammad Hussein Gasem; E. C. M. van Gorp

Objective  To determine the involvement of coagulation in bleeding and poor outcome in patients with severe leptospirosis.


Journal of Medical Virology | 2012

Review: Viral infections and mechanisms of thrombosis and bleeding

Marco Goeijenbier; M. van Wissen; C. van de Weg; E. Jong; Victor E. A. Gerdes; Joost C. M. Meijers; D. P. M. Brandjes; E. C. M. van Gorp

Viral infections are associated with coagulation disorders. All aspects of the coagulation cascade, primary hemostasis, coagulation, and fibrinolysis, can be affected. As a consequence, thrombosis and disseminated intravascular coagulation, hemorrhage, or both, may occur. Investigation of coagulation disorders as a consequence of different viral infections have not been performed uniformly. Common pathways are therefore not fully elucidated. In many severe viral infections there is no treatment other than supportive measures. A better understanding of the pathophysiology behind the association of viral infections and coagulation disorders is crucial for developing therapeutic strategies. This is of special importance in case of severe complications, such as those seen in hemorrhagic viral infections, the incidence of which is increasing worldwide. To date, only a few promising targets have been discovered, meaning the implementation in a clinical context is still hampered. This review discusses non‐hemorrhagic and hemorrhagic viruses for which sufficient data on the association with hemostasis and related clinical features is available. This will enable clinicians to interpret research data and place them into a perspective. J. Med. Virol. 84:1680–1696, 2012.


Thrombosis Journal | 2005

Increased PAI-1 plasma levels and risk of death from dengue: no association with the 4G/5G promoter polymorphism

A. T. A. Mairuhu; Tatty E. Setiati; Penelopie Koraka; C. E. Hack; Anja Leyte; S.M.H. Faradz; H. ten Cate; D. P. M. Brandjes; A.D.M.E. Osterhaus; P. H. Reitsma; E. C. M. van Gorp

BackgroundDengue virus infected patients have high plasminogen activator inhibitor type I (PAI-1) plasma concentrations. Whether the insertion/deletion (4G/5G) polymorphism in the promotor region of the PAI-1 gene is associated with increased PAI-1 plasma concentrations and with death from dengue is unknown. We, therefore, investigated the relationship between the 4G/5G polymorphism and PAI-1 plasma concentrations in dengue patients and risk of death from dengue.MethodsA total of 194 patients admitted to the Dr. Kariadi Hospital in Semarang, Indonesia, with clinical suspected severe dengue virus infection were enrolled. Blood samples were obtained on day of admission, days 1, 2 and 7 after admission and at a 1-month follow-up visit. Plasma concentrations of PAI-1 were measured using a sandwich ELISA kit. The PAI-1 4G/5G polymorphism was typed by allele-specific PCR analysis.ResultsConcentrations of PAI-1 on admission and peak values of PAI-1 during admission were higher than the values measured in healthy controls. Survival was significantly worse in patients with PAI-1 concentrations in the highest tertile (at admission: OR 4.7 [95% CI 0.9–23.8], peak value during admission: OR 6.3 [95%CI 1.3–30.8]). No association was found between the PAI-1 4G/5G polymorphism, and PAI-1 plasma concentrations, dengue disease severity and mortality from dengue.ConclusionThese data suggest that the 4G/5G polymorphism has no significant influence on PAI-1 concentrations in dengue virus infected patients and is not associated with the risk of death from dengue. Other factors contributing to the variability of PAI-1 plasma concentrations in patients with dengue need to be explored.


Eurosurveillance | 2014

The hanta hunting study: underdiagnosis of Puumala hantavirus infections in symptomatic non-travelling leptospirosis-suspected patients in the Netherlands, in 2010 and April to November 2011

Marco Goeijenbier; Rudy A. Hartskeerl; J.H.J. Reimerink; Jenny Verner-Carlsson; Jiri F. P. Wagenaar; Marga G. A. Goris; Byron E. E. Martina; Åke Lundkvist; Marion Koopmans; A.D.M.E. Osterhaus; E. C. M. van Gorp; Chantal Reusken

Leptospirosis and haemorrhagic fever with renal syndrome (HFRS) are hard to distinguish clinically since these two important rodent-borne zoonoses share hallmark symptoms such as renal failure and haemorrhage. Leptospirosis is caused by infection with a spirochete while HFRS is the result of an infection with certain hantaviruses. Both diseases are relatively rare in the Netherlands. Increased incidence of HFRS has been observed since 2007 in countries that border the Netherlands. Since a similar rise in incidence has not been registered in the Netherlands, we hypothesise that due to overlapping clinical manifestations, hantavirus infections may be confused with leptospirosis, leading to underdiagnosis. Therefore, we tested a cohort of non-travelling Dutch patients with symptoms compatible with leptospirosis, but with a negative diagnosis, during 2010 and from April to November 2011. Sera were screened with pan-hantavirus IgG and IgM enzyme-linked immunosorbent assays (ELISAs). Sera with IgM reactivity were tested by immunofluorescence assay (IFA). ELISA (IgM positive) and IFA results were confirmed using focus reduction neutralisation tests (FRNTs). We found hantavirus-specific IgG and/or IgM antibodies in 4.3% (11/255) of samples taken in 2010 and in 4.1% (6/146) of the samples during the 2011 period. After FRNT confirmation, seven patients were classed as having acute Puumala virus infections. A review of hantavirus diagnostic requests revealed that at least three of the seven confirmed acute cases as well as seven probable acute cases of hantavirus infection were missed in the Netherlands during the study period.


Annals of the Rheumatic Diseases | 2009

Effects of a 3-month course of rosuvastatin in patients with systemic lupus erythematosus

M D de Kruif; M Limper; H R Hansen; J de Ruiter; C. A. Spek; E. C. M. van Gorp; I. J. M. Ten Berge; Ajda T. Rowshani; H. ten Cate; Eelco W. Meesters

Systemic lupus erythematosus (SLE) is associated with a highly increased cardiovascular risk. Statins can reduce this risk, but may possess additional anti-inflammatory effects that are relevant for the treatment of SLE. In a preliminary study, we investigated the effects of a 3-month course of rosuvastatin on lipids and markers of inflammation using a randomised cross-over design. The study was approved by the institutional medical and ethical committee and written informed consent was obtained from all subjects. Based upon a previous, representative study,1 a sample size of 14 patients would be necessary to demonstrate a 25% reduction in C-reactive protein (CRP) levels (power = 80%). A dropout level of 35% (n = 5) was estimated.2 Patients with stable …

Collaboration


Dive into the E. C. M. van Gorp's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

W.M.V. Dolmans

Radboud University Nijmegen

View shared research outputs
Top Co-Authors

Avatar

A.D.M.E. Osterhaus

Erasmus University Rotterdam

View shared research outputs
Top Co-Authors

Avatar

Harald S. Miedema

Rotterdam University of Applied Sciences

View shared research outputs
Top Co-Authors

Avatar

Pepijn Roelofs

Rotterdam University of Applied Sciences

View shared research outputs
Top Co-Authors

Avatar

S. E. M. van Opstal

Rotterdam University of Applied Sciences

View shared research outputs
Top Co-Authors

Avatar

Jiri F. P. Wagenaar

Erasmus University Rotterdam

View shared research outputs
Top Co-Authors

Avatar

Penelopie Koraka

Erasmus University Rotterdam

View shared research outputs
Researchain Logo
Decentralizing Knowledge